Evidence map›Paper›PMID 32458149›Full record

ReviewBiological trace element research2021

Can Zn Be a Critical Element in COVID-19 Treatment?

Mohammad Tariqur Rahman, Syed Zahir Idid

Open access · bronzeAbstract readReview
In one paragraph

Review in Biological trace element research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed
3.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 156 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Observational
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. A six-month study of anti-SARS-CoV-2 BNT162b2 mRNA vaccination: A comparative analysis of essential trace elements and anti-RBD IgG sera levels.Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) · 2022
    Article
  18. Review
  19. Article
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Mohammad Tariqur RahmanFaculty of Dentistry, University of Malaya, 50603, Kula Lumpur, Malaysia. m.tariqur.rahman@gmail.com.ORCID http://orcid.org/0000-0003-3600-3265
Syed Zahir IdidFaculty of Allied Health Sciences, International Islamic University Malaysia, 25200, Kuantan, Malaysia.
International Islamic University Malaysia · MYUniversity of Malaya · MY

Funding

Universiti Malaya Not Applicable
6 · The paper itself

Abstract

The current COVID-19 pandemic caused by SARS-CoV-2 has prompted investigators worldwide to search for an effective anti-viral treatment. A number of anti-viral drugs such as ribavirin, remdesivir, lopinavir/ritonavir, antibiotics such as azithromycin and doxycycline, and anti-parasite such as ivermectin have been recommended for COVID-19 treatment. In addition, sufficient pre-clinical rationale and evidence have been presented to use chloroquine for the treatment of COVID-19. Furthermore, Zn has the ability to enhance innate and adaptive immunity in the course of a viral infection. Besides, Zn supplement can favour COVID-19 treatment using those suggested and/or recommended drugs. Again, the effectiveness of Zn can be enhanced by using chloroquine as an ionophore while Zn inside the infected cell can stop SARS-CoV-2 replication. Given those benefits, this perspective paper describes how and why Zn could be given due consideration as a complement to the prescribed treatment of COVID-19.

Indexed as

COVID-19 Drug TreatmentAntiviral AgentsChloroquineHumansLopinavirRitonavirZincAntiviral AgentsChloroquineLopinavirRitonavirZincAnti-viral drugsChloroquinePneumocytesRNA dependent RNA polymeraseSARS-CoV-2Zinc transporter

Identifiers

PMID32458149
PMCPMC7250542
OpenAlexW3031209830

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.